← Browse by Condition
Medical Condition

scleroderma

Total Trials
5
Recruiting Now
5
Trial Phases
Phase 2

ClinicalMetric tracks all active clinical trials for scleroderma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — scleroderma Clinical Trials

How many clinical trials are currently recruiting for scleroderma?
ClinicalMetric currently tracks 5 actively recruiting clinical trials for scleroderma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 5. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for scleroderma?
scleroderma research spans Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a scleroderma clinical trial?
Eligibility criteria for scleroderma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
1
Top Sponsors
Hacettepe University 2 trials
Sanford Health 1 trial
Johns Hopkins University 1 trial
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 1 trial

Recruiting Clinical Trials

NCT07292961
Recruiting
Investigating the Effectiveness of the Biopsychosocial Model-Based Exercise Approach in Children and Adults Diagnosed With Scleroderma
Enrollment
48 pts
Location
Turkey (Türkiye)
Sponsor
Hacettepe University
View Trial →
NCT01793168
Recruiting
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Enrollment
20,000 pts
Location
United States
Sponsor
Sanford Health
View Trial →
NCT07182981
Recruiting
Patients Diagnosed With Scleroderma and Their Chewing and Swallowing Performance
Enrollment
50 pts
Location
Turkey (Türkiye)
Sponsor
Hacettepe University
View Trial →
NCT04797286 Phase 2
Recruiting
Sildenafil for Early Pulmonary Vascular Disease in Scleroderma
Enrollment
30 pts
Location
United States
Sponsor
Johns Hopkins University
View Trial →
NCT07470151
Recruiting
Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases
Enrollment
12 pts
Location
China
Sponsor
Union Hospital, Tongji Medical...
View Trial →

Related Conditions

scleroderma localized (2) scleroderma limited and diffuse (2) systemic sclerosis ssc (2) beta mannosidosis (2) scleroderma systemic (1) systemic sclerosis 2013 acr eular classification criteria (1) juvenile systemic sclerosis (1) rare disorders (1) undiagnosed disorders (1) disorders of unknown prevalence (1) cornelia de lange syndrome (1) prenatal benign hypophosphatasia (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology